Ben Adams

The life sciences industry continues to see a trend of rebranding as another biotech company decides to embrace change by saying goodbye to the old and welcoming the new. | The life sciences industry continues to see a trend of rebranding as another biotech company decides to embrace change by saying goodbye to the old and welcoming the new.

Sickle cell disease (SCD) is a serious, life-long, and potentially life-limiting disease that predominately affects the Black community, but awareness of this disease remains low. | Sickle cell disease (SCD) is a serious, life-long, and potentially life-limiting disease that predominately affects the Black community, but awareness of this disease remains low.

Otsuka and Lundbeck’s CNS drug Rexulti has for the second time this year claimed the top spot as the leading TV drug ad spender. | Otsuka and Lundbeck’s CNS drug Rexulti has for the second time this year claimed the top spot as the leading TV drug ad spender.

Not since the pre-COVID days in 2019 has a pure-play pharmaceutical company managed to win the top prize at the prestigious Cannes Lions International Festival of Creativity, as medical technology | Not since the pre-COVID days in 2019 has a pure-play pharmaceutical company managed to win the top prize at the prestigious Cannes Lions International Festival of Creativity, as medical technology and device firms have seemingly taken over.

Out of the 13 pharmas vying for the top prizes at this year’s Cannes Pharma Lions, there was disappointment Monday night when just two—Biogen and Organon—walked away with a medal, and just a Bronze | Out of the 13 pharmas vying for the top prizes at this year’s Cannes Pharma Lions, there was disappointment Monday night when just two, Biogen and Organon, walked away with a medal, and just a Bronze medal apiece at that.

Glitz, glamour, creatives, sun and blue seas: It must be time for the Cannes Lions International Festival of Creativity. | Glitz, glamour, creatives, sun and blue seas: It must be time for the Cannes Lions International Festival of Creativity.

AbbVie is once again the top spender on pharma TV ads, narrowly beating April’s winner, Rexulti. | AbbVie is once again the top spender on pharma TV ads, narrowly beating April’s winner, Rexulti.

As the FDA mulls over SpringWorks’ experimental neurofibromatosis type 1 drug mirdametinib during its rolling submission, the biotech isn’t wasting time in getting the awareness message about this | As the FDA mulls over SpringWorks’ experimental neurofibromatosis type 1 drug mirdametinib during its rolling submission, the biotech isn’t wasting time in getting the awareness message about this rare disease out into the world.

Merck’s cancer drug giant Keytruda has helped the Big Pharma top how oncologists see cancer drug makers, but no one company is dominating the field. | Merck’s cancer drug giant Keytruda has helped the Big Pharma top how oncologists see cancer drug makers, but no one company is dominating the field.

AstraZeneca and Merck & Co. were the first to grab an FDA approval for their PARP inhibitor Lynparza, and, despite growing competition, the drug is set to remain top dog in the PARP space. | AstraZeneca and Merck were the first to grab an FDA approval for their PARP inhibitor Lynparza, and, despite growing competition, the drug is set to remain top dog in the PARP space.